nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

08.10.2019 | Original Article – Clinical Oncology

ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression

verfasst von: Maria-Alexandra Papadimitriou, Margaritis Avgeris, Panagiotis K. Levis, Theodoros Tokas, Konstantinos Stravodimos, Andreas Scorilas

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bladder cancer represents a major cause of malignancy-related morbidity and the most expensive per-patient-to-treat cancer, due to the lifelong surveillance of the patients. Accurate disease prognosis is essential in establishing personalized treatment decisions; yet optimum tools for precise risk stratification remain a competing task. In the present study, we have performed the complete evaluation of TP63 clinical significance in improving disease prognosis.

Methods

The levels of ΔNp63 and TAp63 transcripts of TP63 were quantified in 342 bladder tissue specimens of our screening cohort (n = 182). Hedegaard et al. (Cancer Cell 30:27–42. doi:10.1016/j.ccell.2016.05.004, 2016) (n = 476) and TCGA provisional (n = 413) were used as validation cohorts for NMIBC and MIBC, respectively. Survival analysis was performed using recurrence and progression for NMIBC or mortality for MIBC as endpoint events. Bootstrap analysis was performed for internal validation, while decision curve analysis was used for the evaluation of the clinical net benefit on disease prognosis.

Results

ΔNp63 was significantly expressed in bladder tissues, and was found to be over-expressed in bladder tumors. Interestingly, reduced ΔNp63 levels were correlated with muscle-invasive disease, high-grade tumors and high-EORTC-risk NMIBC patients. Moreover, ΔNp63 loss was independently associated with higher risk for NMIBC relapse (HR = 2.730; p = 0.007) and progression (HR = 7.757; p = 0.016). Hedegaard et al. and TCGA validation cohorts confirmed our findings. Finally, multivariate models combining ΔΝp63 loss with established prognostic markers led to a superior clinical benefit for NMIBC prognosis and risk stratification.

Conclusions

ΔΝp63 loss is associated with adverse outcome of NMIBC resulting in superior prediction of NMIBC early relapse and progression.

Nur mit Berechtigung zugänglich

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108. https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefPubMed

Avgeris M, Mavridis K, Tokas T, Stravodimos K, Fragoulis EG, Scorilas A (2015) Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment. Carcinogenesis 36:528–537. https://doi.org/10.1093/carcin/bgv024 CrossRefPubMed

Avgeris M et al (2018) Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients. Br J Cancer 119:1477–1486. https://doi.org/10.1038/s41416-018-0320-6 CrossRefPubMedPubMedCentral

Babjuk M et al (2017) EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461. https://doi.org/10.1016/j.eururo.2016.05.041 CrossRefPubMed

Barbieri CE, Tang LJ, Brown KA, Pietenpol JA (2006) Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66:7589–7597. https://doi.org/10.1158/0008-5472.can-06-2020 CrossRefPubMed

Bergholz J, Xiao ZX (2012) Role of p63 in development tumorigenesis and cancer progression. Cancer Microenviron 5:311–322. https://doi.org/10.1007/s12307-012-0116-9 CrossRefPubMedPubMedCentral

Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252–7259. https://doi.org/10.1158/1078-0432.ccr-04-0713 CrossRefPubMed

Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28:401–408. https://doi.org/10.1016/j.urolonc.2009.04.019 CrossRefPubMed

Chen Y, Peng Y, Fan S, Li Y, Xiao ZX, Li C (2018) A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci 75:965–973. https://doi.org/10.1007/s00018-017-2666-y CrossRefPubMed

Choi W et al (2012) p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS ONE 7:e30206. https://doi.org/10.1371/journal.pone.0030206 CrossRefPubMedPubMedCentral

Comperat E et al (2007) p63 gene expression study and early bladder carcinogenesis. Urology 70:459–462. https://doi.org/10.1016/j.urology.2007.04.030 CrossRefPubMed

Donovan MJ, Cordon-Cardo C (2014) Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. Expert Rev Mol Diagn 14:1023–1031. https://doi.org/10.1586/14737159.2014.965151 CrossRefPubMed

Felsenstein KM, Theodorescu D (2018) Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol 15:92–111. https://doi.org/10.1038/nrurol.2017.179 CrossRefPubMed

Flores ER (2007) The roles of p63 in cancer. Cell Cycle 6:300–304. https://doi.org/10.4161/cc.6.3.3793 CrossRefPubMed

Fukushima H et al (2009) Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res 69:9263–9270. https://doi.org/10.1158/0008-5472.can-09-1188 CrossRefPubMed

Gaya JM et al (2015) DeltaNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. J Urol 193:1144–1150. https://doi.org/10.1016/j.juro.2014.10.098 CrossRefPubMed

Hedegaard J et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27–42. https://doi.org/10.1016/j.ccell.2016.05.004 CrossRefPubMed

Hibi K et al (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97:5462–5467CrossRefPubMedPubMedCentral

Jordan B, Meeks JJ (2018) T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. https://doi.org/10.1038/s41585-018-0105-y CrossRef

Kaelin WG Jr (1999) The p53 gene family. Oncogene 18:7701–7705. https://doi.org/10.1038/sj.onc.1202955 CrossRefPubMed

Kamat AM et al (2016) Bladder cancer. Lancet 388:2796–2810. https://doi.org/10.1016/S0140-6736(16)30512-8 CrossRefPubMed

Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25–41. https://doi.org/10.1038/nrc3817 CrossRefPubMed

Koga F et al (2003a) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 9:5501–5507PubMed

Koga F et al (2003b) Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 88:740–747. https://doi.org/10.1038/sj.bjc.6600764 CrossRefPubMedPubMedCentral

Kumakura Y et al (2017) Elevated expression of DeltaNp63 in advanced esophageal squamous cell carcinoma. Cancer Sci 108:2149–2155. https://doi.org/10.1111/cas.13394 CrossRefPubMedPubMedCentral

Malaguarnera R et al (2005) The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 12:953–971. https://doi.org/10.1677/erc.1.00968 CrossRefPubMed

Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa E, Pesole G, D’Erchia AM (2009) Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res 37:6092–6104. https://doi.org/10.1093/nar/gkp674 CrossRefPubMedPubMedCentral

Moses MA, George AL, Sakakibara N, Mahmood K, Ponnamperuma RM, King KE, Weinberg WC (2019) Molecular mechanisms of p63-mediated squamous cancer pathogenesis. Int J Mol Sci. https://doi.org/10.3390/ijms20143590 CrossRefPubMedPubMedCentral

Osada M et al (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4:839–843CrossRefPubMed

Park BJ et al (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60:3370–3374PubMed

Prasad SM, Decastro GJ, Steinberg GD, Medscape (2011) Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol 8:631–642. https://doi.org/10.1038/nrurol.2011.144 CrossRefPubMed

Rampias T et al (2014) A new tumor suppressor role for the Notch pathway in bladder cancer. Nat Med 20:1199–1205. https://doi.org/10.1038/nm.3678 CrossRefPubMed

Robertson AG et al (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder. Cancer Cell 171(540–556):e525. https://doi.org/10.1016/j.cell.2017.09.007 CrossRef

Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer Nat Rev Dis Primers 3:17022. https://doi.org/10.1038/nrdp.2017.22 CrossRefPubMed

Sayan AE et al (2010) p73 and p63 regulate the expression of fibroblast growth factor receptor 3. Biochem Biophys Res Commun 394:824–828. https://doi.org/10.1016/j.bbrc.2010.03.084 CrossRefPubMed

Schmale H, Bamberger C (1997) A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363–1367. https://doi.org/10.1038/sj.onc.1201500 CrossRefPubMed

Senoo M et al (1998) A second p53-related protein, p73L, with high homology to p73. Biochem Biophys Res Commun 248:603–607CrossRefPubMed

Signoretti S et al (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775. https://doi.org/10.1016/s0002-9440(10)64814-6 CrossRefPubMedPubMedCentral

Sjodahl G et al (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18:3377–3386. https://doi.org/10.1158/1078-0432.CCR-12-0077-T CrossRefPubMed

Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, Lotan Y (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 66:253–262. https://doi.org/10.1016/j.eururo.2014.01.006 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Tran MN et al (2013) The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem 288:3275–3288. https://doi.org/10.1074/jbc.m112.408104 CrossRefPubMed

Tsikrika FD, Avgeris M, Levis PK, Tokas T, Stravodimos K, Scorilas A (2018) miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients’ risk for short-term relapse and progression Genes. Chromosomes Cancer 57:150–161. https://doi.org/10.1002/gcc.22516 CrossRef

Urist MJ et al (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161:1199–1206. https://doi.org/10.1016/s0002-9440(10)64396-9 CrossRefPubMedPubMedCentral

Van Batavia J et al (2014) Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol 16(982–991):981–985. https://doi.org/10.1038/ncb3038 CrossRef

Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:565–574. https://doi.org/10.1177/0272989X06295361 CrossRefPubMedPubMedCentral

Warrick JI et al (2019) Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 75:18–22. https://doi.org/10.1016/j.eururo.2018.09.003 CrossRefPubMed

Witjes JA et al (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792. https://doi.org/10.1016/j.eururo.2013.11.046 CrossRefPubMed

Yang A, McKeon F (2000) P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 1:199–207. https://doi.org/10.1038/35043127 CrossRefPubMed

Yang A et al (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305–316CrossRefPubMed

Titel: ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression
verfasst von: Maria-Alexandra Papadimitriou
Margaritis Avgeris
Panagiotis K. Levis
Theodoros Tokas
Konstantinos Stravodimos
Andreas Scorilas
Publikationsdatum: 08.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03028-5

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

The effectiveness of Wilms tumor screening in Beckwith–Wiedemann spectrum

Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer

Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma

Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome

Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding?

Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie